三代“格列卫”首发上市，亚盛医药迈入商业化阶段 - 2021年12月20日

China's first domestically-developed medicine targeting drug-resistant chronic myeloid leukemia has been approved by the national authority.

The drug, Olverembatinib developed by Ascentage Pharma, doesn't only fill a blank in the medical field but helps solve a social problem, said Chen Kaixian, vice director of the national key project for new drug innovation.

Chronic myeloid leukemia is a clonal stem cell disorder that is characterized by the acquired chromosomal translocation BCR-ABL.